49.55

7.32% 3.38

After Hours: 50.50 0.95 +1.92%

Tarsus Pharmaceuticals Inc (TARS)

Overview News Price History Option Chain Financials Discussions Forecast

Tarsus Pharmaceuticals Inc stock is traded at $49.55, with a volume of 693.71K. It is up +7.32% in the last 24 hours and up +0.00% over the past month. Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

Previous Close:

$46.17

Open:

$45.79

24h Volume:

693.71K

Relative Volume:

1.17

Market Cap:

$2.04B

Revenue:

$17.39M

Net Income/Loss:

$-135.89M

P/E Ratio:

-10.68

EPS:

-4.64

Net Cash Flow:

$-123.00M

1W Performance:

+5.20%

1M Performance:

+0.00%

6M Performance:

+43.21%

1Y Performance:

+57.20%

1-Day Range:

$45.54

$49.73

1-Week Range:

$45.22

$49.73

52-Week Range:

$20.08

$57.28

Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile

Name

Tarsus Pharmaceuticals Inc

Sector

Healthcare (1167)

Industry

Biotechnology (670)

Phone

(949) 409-9820

Address

15440 LAGUNA CANYON ROAD, IRVINE

Employee

323

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

TARS's Discussions on Twitter

Compare TARS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TARS Tarsus Pharmaceuticals Inc	49.55	2.04B	17.39M	-135.89M	-123.00M	-4.64
VRTX Vertex Pharmaceuticals Inc	512.52	131.61B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	672.36	73.51B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	619.97	37.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	253.44	32.81B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	266.26	28.62B	3.81B	-644.79M	-669.77M	-6.24

Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-20-23	Initiated	Goldman	Neutral
Jul-18-23	Initiated	William Blair	Outperform
May-18-23	Initiated	Guggenheim	Buy
Aug-01-22	Initiated	Barclays	Overweight
Dec-21-21	Initiated	H.C. Wainwright	Buy
Nov-23-21	Initiated	Oppenheimer	Outperform
Nov-10-20	Initiated	BofA Securities	Buy
Nov-10-20	Initiated	Jefferies	Buy
Nov-10-20	Initiated	Ladenburg Thalmann	Buy
Nov-10-20	Initiated	Raymond James	Strong Buy

View All

Tarsus Pharmaceuticals Inc Stock (TARS) Latest News

Mar 18, 2025

Tarsus Pharmaceuticals Prices Upsized $125 Million Equity Offering -March 13, 2025 at 03:44 am EDT - Marketscreener.com

Mar 13, 2025

Tarsus Announces Pricing of Upsized $125.0 Million Public Offering - GlobeNewswire

Mar 13, 2025

Mar 12, 2025

Tarsus Pharmaceuticals launches $100 million stock offering - Investing.com Australia

Mar 12, 2025

Tarsus Secures Massive $125M Capital Raise as Investors Rush Into Upsized Offering - StockTitan

Mar 12, 2025

Tarsus Announces Pricing Of Upsized $125 Million Public Offering -March 12, 2025 at 09:50 pm EDT - Marketscreener.com

Mar 12, 2025

Tarsus Pharmaceuticals dips on planned $100 million equity raise - TradingView

Mar 12, 2025

Tarsus Pharmaceuticals launches $100 million stock offering By Investing.com - Investing.com Canada

Mar 12, 2025

Tarsus Announces Proposed $100.0 Million Public Offering - GlobeNewswire

Mar 12, 2025

Tarsus Pharmaceuticals’ SWOT analysis: specialty pharma stock faces growth hurdles By Investing.com - Investing.com South Africa

Mar 12, 2025

Tarsus Pharmaceuticals’ SWOT analysis: specialty pharma stock faces growth hurdles - Investing.com

Mar 12, 2025

Mar 11, 2025

Tarsus Pharma: Strong Execution In Xdemvy Commercialization (NASDAQ:TARS) - Seeking Alpha

Mar 11, 2025

Mar 10, 2025

Oppenheimer & Co. Inc. Takes Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World

Mar 10, 2025

Mar 09, 2025

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of “Buy” by Brokerages - Defense World

Mar 09, 2025

Mar 08, 2025

Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says - Defense World

Mar 08, 2025

Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Up 5.8% Following Analyst Upgrade - Defense World

Mar 08, 2025

Mar 07, 2025

Contrasting PharmaCyte Biotech (OTCMKTS:PMCBD) & Tarsus Pharmaceuticals (NASDAQ:TARS) - Defense World

Mar 07, 2025

Mar 06, 2025

Tarsus to Participate in Upcoming Investor Conference - GlobeNewswire

Mar 06, 2025